source
- Roche’s CEO has ‘absolutely not’ changed tune on Poseida despite scrapping CAR-T from the buyoutRoche’s CEO has insisted to Fierce that the company’s view on its $1.5 billion Poseida buyout has “absolutely not” changed, even as the Swiss pharma scraps one of the CAR-T therapy’s from the acqui…Fierce Biotech · 4h ago↗ source
- GSK and Ionis receive FDA nod for Hibsago, a potential functional cure for chronic hepatitis BThe U.S. Food and Drug Administration has cleared Hibsago, a collaborative product of GSK and Ionis, as the first therapy of its kind aimed at chronic hepatitis B. The medicine is to be added to s…